Edwards’ Additional AAA Study Patients May Accelerate FDA Approval
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences is considering the addition of another 50 patients to a U.S. pivotal trial of the Lifepath abdominal aortic aneurysm (AAA) graft, originally planned to enroll 100 patients by September 2002